Stay updated with breaking news from Platelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with chronic immune thrombocytopenia (ITP) fared better on intravenous efgartigimod (Vyvgart) than a placebo, but only 21.8% reached the primary endpoint of sustained platelet.
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.
According to the American Red Cross, only about 3% of Americans are active donors. And with no other way to source blood or platelets, the need for new donors remains constant.
Researchers used cellular cryo-electron tomography (cryo-ET) to demonstrate the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in coronavirus disease 2019 (COVID-19)-triggered severe coagulopathies.
In a recent study, researchers used proteomic analysis to identify novel immune cell phenotypes associated with severe coronavirus disease 2019 (COVID-19).